Skip to main content

Gocovri News

Adamas Announces FDA Approval for Second Indication for Gocovri as an Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes

EMERYVILLE, Calif.--(BUSINESS WIRE)--Feb. 1, 2021-- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people...

FDA Approves Gocovri (amantadine) for the Treatment of Dyskinesia in Parkinson's Disease Patients

EMERYVILLE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) – Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved Gocovri (amantadine)...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Extrapyramidal Reaction, Parkinson's Disease

Gocovri patient information at Drugs.com